Valneva Withdraws Chikungunya Vaccine from U.S. Market
Valneva voluntarily withdraws its IXCHIQ chikungunya vaccine from the U.S. following FDA suspension and a serious adverse event report, while maintaining licenses in Europe, Canada, UK, and Brazil.